Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TNF | P01375 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22521931 | 0.85 | TNF (0.60) | RXFP1MAPK1ADORA2BSMN1; SMN2LMNA | |
| SCHEMBL24559342 | 0.84 | ADORA2B (0.45) | RXFP1MAPK1ADORA2BSMN1; SMN2LMNA | |
| SCHEMBL24559323 | 0.83 | RXFP1 (0.70) | RXFP1MAPK1ADORA2BSMN1; SMN2LMNA | |
| SCHEMBL24559134 | 0.83 | RXFP1 (0.56) | RXFP1MAPK1ADORA2BSMN1; SMN2LMNA | |
| SCHEMBL22521901 | 0.82 | TNF (0.61) | RXFP1MAPK1ADORA2BSMN1; SMN2LMNA | |
| SCHEMBL24559298 | 0.79 | ADORA2B (0.61) | RXFP1MAPK1ADORA2BSMN1; SMN2LMNA | |
| SCHEMBL24559132 | 0.78 | TNF (0.59) | RXFP1MAPK1ADORA2BSMN1; SMN2LMNA | |
| SCHEMBL24559089 | 0.76 | ADORA2B (0.61) | RXFP1MAPK1ADORA2BLMNAMAPT | |
| SCHEMBL24559396 | 0.76 | ADORA2B (0.73) | RXFP1MAPK1ADORA2BSMN1; SMN2LMNA | |
| SCHEMBL22521953 | 0.75 | SMN1; SMN2 (0.74) | RXFP1MAPK1ADORA2BSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220202821-A1 | SMALL MOLECULE PARG INHIBITORS AND METHODS OF USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202821-A1 | SMALL MOLECULE PARG INHIBITORS AND METHODS OF USE THEREOF | PARG, PARP15, PLG | RXFP1 2773/4885MAPK1 2790/4885ADORA2B 2231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.